M Bio Technology
M Bio Technology Inc. is a research and development company specializing in the diagnosis, treatment, and prevention of mycoplasma infections. With over 30 years of research, the company has developed core technologies including the identification and chemical synthesis of glycolipid antigens specific to mycoplasma bacteria. They aim to innovate in diagnostics, therapeutics, and vaccines, and are actively engaged in global collaborations, clinical trials, and technological development to combat mycoplasma infectious diseases.
Industries
Nr. of Employees
small (1-50)
M Bio Technology
2-3-103 Fukasawa, Setagaya-ku, Tokyo 158-0081
Patents
Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of mycoplasma pneumoniae
US-10870669-B2
View Details
Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of mycoplasma pneumoniae
US-10870669-B2
View DetailsProducts
Chemically synthesized mycoplasma glycolipid antigens
Synthetic glycolipid antigens identified from mycoplasma membranes, produced for use in diagnostics, vaccine constructs and antibody induction workflows.
ELISA diagnostic kit prototype based on synthetic glycolipid antigens
An antigen–antibody ELISA method to detect mycoplasma-specific antibody isotypes (IgM/IgG/IgA) using chemically synthesized glycolipid antigens; prototype and medium-scale production activity reported.
Vaccine candidates using synthetic glycolipid antigens (liposome/pseudoparticle)
Preclinical vaccine constructs that present chemically synthesized glycolipid antigens via liposome or pseudoparticle formulations intended to induce protective or therapeutic immune responses.
Monoclonal antibodies induced and produced using antigen-mimicking particles
Monoclonal antibodies generated by immuno-induction using synthetic antigen-mimicking particles and harvested through bioreactor workflows for development as therapeutic agents.
Chemically synthesized mycoplasma glycolipid antigens
Synthetic glycolipid antigens identified from mycoplasma membranes, produced for use in diagnostics, vaccine constructs and antibody induction workflows.
ELISA diagnostic kit prototype based on synthetic glycolipid antigens
An antigen–antibody ELISA method to detect mycoplasma-specific antibody isotypes (IgM/IgG/IgA) using chemically synthesized glycolipid antigens; prototype and medium-scale production activity reported.
Vaccine candidates using synthetic glycolipid antigens (liposome/pseudoparticle)
Preclinical vaccine constructs that present chemically synthesized glycolipid antigens via liposome or pseudoparticle formulations intended to induce protective or therapeutic immune responses.
Monoclonal antibodies induced and produced using antigen-mimicking particles
Monoclonal antibodies generated by immuno-induction using synthetic antigen-mimicking particles and harvested through bioreactor workflows for development as therapeutic agents.
Services
Provision of synthetic-glycolipid-antigen serology testing through a network of designated clinics in Japan.
Free web-based preliminary screening (10-item) with an option for a detailed 40-item assessment and paid online physician consultation leading to blood testing and diagnostic confirmation.
Collaboration and contract partnerships to perform prototype and medium-scale production runs of ELISA diagnostic components and vaccine material; seeking partners for further scale-up.
Execution of joint research agreements with universities and engagement in open calls for clinical trial programs to evaluate diagnostics, vaccines and therapeutics.
Operation of a virtual international consortium to collect input from pharmaceutical companies, researchers, clinicians and patient stakeholders for consensus building on mycoplasma infectious diseases.
Provision of synthetic-glycolipid-antigen serology testing through a network of designated clinics in Japan.
Free web-based preliminary screening (10-item) with an option for a detailed 40-item assessment and paid online physician consultation leading to blood testing and diagnostic confirmation.
Collaboration and contract partnerships to perform prototype and medium-scale production runs of ELISA diagnostic components and vaccine material; seeking partners for further scale-up.
Execution of joint research agreements with universities and engagement in open calls for clinical trial programs to evaluate diagnostics, vaccines and therapeutics.
Operation of a virtual international consortium to collect input from pharmaceutical companies, researchers, clinicians and patient stakeholders for consensus building on mycoplasma infectious diseases.
Expertise Areas
- Glycolipid antigen discovery and chemical synthesis
- Serological diagnostic development and validation
- Vaccine design and preclinical development
- Therapeutic monoclonal antibody discovery and production
Key Technologies
- Chemical synthesis of glycolipid antigens
- ELISA serological assays (IgM/IgG/IgA measurement)
- High-resolution electrospray ionization mass spectrometry (ESI-MS)
- Deuterium-labeled internal standards for MS quantification
News & Updates
M Bio Technology was selected for the Deep Tech Course of JETRO's Global Startup Accelerator Program 2024.
The company was selected to exhibit at the Japan Healthcare Venture Summit 2024 held at Pacifico Yokohama.
Kazuhiro Matsuda, Director of the Mycoplasma Infection Research Center, was interviewed as an expert.
This article discusses the identification of specific glycolipid antigens of mycoplasma and the development of serological diagnostics and vaccines.
The article explores early diagnosis methods for mycoplasma pneumoniae infections using new serological technologies.
Support for overseas expansion by JETRO
Supported by JETRO's 'New Export Power' consortium, focusing on global presence expansion.
M Bio Technology was selected for the Deep Tech Course of JETRO's Global Startup Accelerator Program 2024.
The company was selected to exhibit at the Japan Healthcare Venture Summit 2024 held at Pacifico Yokohama.
Kazuhiro Matsuda, Director of the Mycoplasma Infection Research Center, was interviewed as an expert.
This article discusses the identification of specific glycolipid antigens of mycoplasma and the development of serological diagnostics and vaccines.
The article explores early diagnosis methods for mycoplasma pneumoniae infections using new serological technologies.
Support for overseas expansion by JETRO
Supported by JETRO's 'New Export Power' consortium, focusing on global presence expansion.